Home › All Companies › AEON › Insider Trading

AEON Biopharma, Inc. (AEON) — Insider Trading

AI-Powered SEC Filing Analysis

← All AEON filings
Latest Insider Trading Filed: 2026-04-03

Key Insights

  • John Bencich, the Chief Financial Officer of AEON Biopharma, Inc. (AEON), was granted 754,717 shares of Class A common stock on April 2, 2026, vesting in equal installments over four years.
  • This insider grant suggests the company is incentivizing its executive leadership to drive long-term value creation for shareholders.
  • The significant equity award to the CFO, representing a substantial stake in the company, aligns his interests with those of investors.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-04-03. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for AEON Biopharma, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.